Loading clinical trials...
Loading clinical trials...
KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis
Conditions
Interventions
KB407 (Nebulization)
Locations
5
United States
University of Florida, Gainesville
Gainesville, Florida, United States
The Cystic Fibrosis Institute
Northfield, Illinois, United States
New York Medical College/ Boston Children's Health Physicians
Hawthorne, New York, United States
Northwell Health Physicians
New York, New York, United States
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Start Date
June 30, 2023
Primary Completion Date
December 1, 2025
Completion Date
January 1, 2026
Last Updated
August 21, 2025
NCT02417740
NCT06616857
NCT02740868
NCT07108153
NCT07274631
NCT07303621
Lead Sponsor
Krystal Biotech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions